Welcome to our dedicated page for Tango Therapeutics news (Ticker: TNGX), a resource for investors and traders seeking the latest updates and insights on Tango Therapeutics stock.
Tango Therapeutics, Inc. (NASDAQ: TNGX) is a clinical-stage biotechnology company focused on precision cancer medicines, and its news flow reflects ongoing progress in oncology research, clinical development, and corporate strategy. The company describes itself as dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer, using the genetic principle of synthetic lethality to identify and pursue critical targets in tumors.
News about Tango Therapeutics often highlights updates from its clinical pipeline, including vopimetostat (TNG462), an oral MTA-cooperative PRMT5 inhibitor for MTAP-deleted cancers, TNG456, a brain-penetrant PRMT5 inhibitor in development for glioblastoma and malignant glioma, and TNG260, a first-in-class CoREST complex inhibitor being evaluated with pembrolizumab in STK11-mutant solid tumors. Press releases have detailed Phase 1/2 clinical data, trial enrollment status, and regulatory designations such as Orphan Drug Designation for TNG456.
The company also issues news on corporate and financial developments, including leadership transitions, board appointments, equity financings, and at-the-market offering agreements documented in SEC filings. Announcements about participation in major healthcare investment conferences and scientific meetings, such as the J.P. Morgan Healthcare Conference and the Society for Immunotherapy of Cancer (SITC) Annual Meeting, provide additional context on how Tango Therapeutics communicates its strategy and data to investors and the scientific community.
Investors and followers of TNGX can use this news page to review company-issued press releases on clinical results, pipeline milestones, financing transactions, and governance changes, offering a consolidated view of how Tango Therapeutics is advancing its precision oncology programs based on synthetic lethality and targeted cancer biology.
Tango Therapeutics (NASDAQ: TNGX) will present three posters at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2025 in National Harbor, MD, Nov 5–9, 2025.
Presentations include the first clinical data for TNG260, a first‑in‑class CoREST inhibitor being evaluated in the dose‑expansion phase of a Phase 1/2 trial in combination with pembrolizumab. The trial is enrolling patients with STK11‑mutant/RAS wild‑type lung cancer (about ~10% of lung adenocarcinoma).
All three posters are scheduled for Friday, November 7, 2025 (9:00am–7:00pm EDT). Key abstracts: #561 (clinical Phase 1/2; presenter Salman R. Punekar, M.D.), #681 (TNG260 sensitization; presenter Leanne Ahronian, Ph.D.), and #1225 (MGAT1 inhibition overcoming STK11 immune evasion).
Tango Therapeutics (NASDAQ:TNGX) announced its upcoming participation in the 2025 Cantor Global Healthcare Conference. The company's President and CEO, Barbara Weber, M.D., will participate in a fireside chat on September 3, 2025, from 2:45-3:15 PM ET.
Investors can access the live webcast through the "Events & Presentations" section on the company's investor relations website. The presentation recording will remain available for 90 days following the event.
Tango Therapeutics (NASDAQ:TNGX) reported Q2 2025 financial results and pipeline updates. The company achieved key milestones in its clinical programs, including first patient dosing in two trials: a combination trial of TNG462 with Revolution Medicines' RAS(ON) inhibitors and a Phase 1/2 trial of TNG456 for glioblastoma.
Financial highlights include $180.8 million in cash reserves expected to fund operations into Q1 2027. Q2 2025 showed revenue of $3.2 million, down from $7.8 million in Q2 2024, and a net loss of $38.9 million ($0.35 per share). The company's collaboration with Gilead will conclude its research portion early, resulting in $53.8 million revenue recognition in Q3 2025.
Tango Therapeutics (NASDAQ: TNGX) announced it will release its second quarter 2025 financial results on Tuesday, August 5, 2025, before U.S. markets open. The company stated it will not host a conference call to discuss the results.
Tango Therapeutics (NASDAQ: TNGX) has initiated dosing in a Phase 1/2 trial combining its TNG462 with Revolution Medicines' daraxonrasib or zoldonrasib in patients with MTAP-deleted and RAS mutant metastatic pancreatic or lung cancer.
The study aims to evaluate safety, pharmacokinetics, pharmacodynamics, and antitumor activity. TNG462, a MTA-cooperative PRMT5 inhibitor, is also being studied as monotherapy with data expected in H2 2025. The monotherapy results will inform a registrational trial in pancreatic cancer and advance the lung cancer development plan.
Tango Therapeutics (NASDAQ: TNGX) announced that its President and CEO, Barbara Weber, M.D., will participate in a fireside chat at the 46th Annual Goldman Sachs Global Healthcare Conference. The presentation is scheduled for June 10 at 3:20-3:55 PM ET. Investors can access the live webcast through the "Events & Presentations" section on the company's website, and a replay will be available for 90 days following the event.
Tango Therapeutics (NASDAQ: TNGX) has initiated dosing in its Phase 1/2 clinical trial of TNG456, a next-generation, brain-penetrant, MTA-cooperative PRMT5 inhibitor. The trial focuses on patients with MTAP-deleted solid tumors, particularly glioblastoma (GBM). The study (NCT06810544) will evaluate TNG456's safety, pharmacokinetics, pharmacodynamics, and antitumor activity both as monotherapy and in combination with abemaciclib.
The trial's significance is highlighted by the current poor prognosis for GBM patients, who face a five-year survival rate below 10%. Notably, 45% of GBM cases are MTAP-deleted, presenting a substantial potential patient population. Preclinical studies have shown promising results regarding TNG456's potency, MTAP-selectivity, and brain exposure, suggesting potential efficacy in GBM treatment.
Tango Therapeutics (NASDAQ: TNGX) has announced it will release its first quarter 2025 financial results on Monday, May 12, 2025, before U.S. financial markets open. The company has stated that it will not host a conference call to discuss the results.
Tango Therapeutics (NASDAQ: TNGX) announced the acceptance of five abstracts for poster presentation at the AACR Annual Meeting 2025 in Chicago. The presentations will showcase preclinical data focusing on their PRMT5 inhibitor programs, particularly TNG456 and TNG462, designed for treating MTAP-deleted cancers.
The research highlights include evaluation of CNS drug penetration, brain-penetrant capabilities, combination therapy potential with KRAS-inhibitors, and analysis of MTAP truncations impact. Additionally, the company will present findings on tumor regression in FOCAD-deleted cancers through HBS1L/PELO complex disruption.
According to Dr. Adam Crystal, President of Research and Development, the data demonstrates the potential of their molecules as standalone treatments and combination partners in MTAP-deleted cancers, suggesting future development opportunities.
FAQ
What is the current stock price of Tango Therapeutics (TNGX)?
What is the market cap of Tango Therapeutics (TNGX)?
